Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $4.6 million.

  • Day One Biopharmaceuticals' Interest & Investment Income fell 1433.67% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 912.01%. This contributed to the annual value of $19.7 million for FY2024, which is 1462.73% up from last year.
  • Day One Biopharmaceuticals' Interest & Investment Income amounted to $4.6 million in Q3 2025, which was down 1433.67% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Interest & Investment Income registered a high of $6.1 million during Q4 2024, and its lowest value of $3.4 million during Q2 2023.
  • Moreover, its 3-year median value for Interest & Investment Income was $4.8 million (2023), whereas its average is $4.8 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Interest & Investment Income surged by 2046.18% in 2024 and then plummeted by 1433.67% in 2025.
  • Day One Biopharmaceuticals' Interest & Investment Income (Quarter) stood at $5.0 million in 2023, then increased by 20.46% to $6.1 million in 2024, then decreased by 24.67% to $4.6 million in 2025.
  • Its Interest & Investment Income stands at $4.6 million for Q3 2025, versus $4.7 million for Q2 2025 and $5.1 million for Q1 2025.